Assorted News from the Last Week: The US National Childhood Cancer Registry (NCCR) is combining data from myriad sources to hasten and improve research into

Assorted News from the Last Week: Trial results confirm effectiveness of Atezolizumab against a rare sarcoma. By a 14-6 vote, the Oncologic Drugs Advisory Committee

Assorted News from the Last Week: Video distraction minimizes anesthesia for children undergoing radiotherapy. Supporting the family affected by a pediatric cancer diagnosis: siblings matter,

Assorted News from the Last Week: Opinion piece from the New York Times: It Takes a Lifetime to Survive Childhood Cancer. (with a bonus that

Assorted News from the Last Week: On September 26, 2023, the FDA approved bosutinib (Bosulif, Pfizer) for pediatric patients 1 year of age and older

Assorted News from the Last Week: U.S. Congressman Michael McCaul (R-Texas) and Childhood Cancer Caucus Co-Chairs Ami Bera (D-Calif.) and Mike Kelly (R-Pa.) introduced the

Assorted News from the Last Week: White House announces new Cancer Moonshot Initiatives, including several initiatives involving CAC2 Members: xCures, a health-data technology platform, is

Assorted News from the Last Week: A retrospective study shows that more intense ALL therapy improves outcomes in adolescents and young adults. This treatment option

Assorted News from the Last Week: Major League Soccer, MLS WORKS – the League’s social responsibility platform – and Continental Tire are teaming up during

Assorted News from the Last Week: Despite major advances in cancer research, we collectively fall short in bringing innovative medicines to children with cancer.  A